Summary: In adults with type 1 diabetes requiring insulin therapy, a fully closed-loop system combining automated insulin and pramlintide delivery without carbohydrate counting or meal announcements demonstrated maintained time in range (~79%) comparable to standard hybrid closed-loop control compared to standard hybrid closed-loop management with carbohydrate counting and meal boluses, with need for larger, longer investigations to confirm clinical benefits and safety.
| PICO | Description |
|---|---|
| Population | Adults with type 1 diabetes requiring insulin therapy, participating in a pilot outpatient assessment. |
| Intervention | Fully closed-loop system combining automated insulin and pramlintide delivery without carbohydrate counting or meal announcements. |
| Comparison | Standard hybrid closed-loop management with carbohydrate counting and meal boluses. |
| Outcome | Time in range (~79%) maintained comparable to standard hybrid closed-loop control. Demonstrates carbohydrate counting can potentially be eliminated. Larger, longer studies needed to confirm benefits and safety. |
Fully closed-loop insulin + pramlintide
Pilot RCT · type 1 diabetes · 14 h/arm
Fully automated insulin plus pramlintide held time in range near 79%, matching standard carb-counting closed-loop control. The differences were not statistically significant, but this 12-person pilot needs larger, longer confirmation.
Clinical Context
Current automated insulin delivery (AID) systems have transformed type 1 diabetes management, yet they remain “hybrid” systems requiring patients to count carbohydrates and announce meals. This carbohydrate counting burden is significant—studies show 50% estimation errors are common, introducing glycemic variability despite automation.
Pramlintide, a synthetic analog of amylin, offers a potential solution. It slows gastric emptying, suppresses postprandial glucagon, and increases satiety—effects that may provide the pharmacokinetic buffer needed for fully closed-loop control without meal announcement.
This pilot study tested whether combining pramlintide with automated insulin delivery could eliminate the need for carbohydrate counting while maintaining glycemic control comparable to current hybrid systems.
Clinical Pearls
1. Proof of Concept for Eliminating Carb Counting: Achieving comparable time in range without meal announcements demonstrates that pramlintide’s effects can compensate for the lack of anticipatory insulin bolusing.
2. Dual-Hormone Approach Addresses Insulin’s Limitations: Adding pramlintide effectively slows glucose appearance while insulin handles glucose disappearance—a complementary mechanism that smooths postprandial excursions.
3. Technical Complexity Remains a Barrier: Dual-hormone delivery requires specialized hardware and algorithms. Engineering solutions for commercial viability are needed.
4. Safety Signals Require Larger Studies: Pramlintide’s side effects (nausea, hypoglycemia risk) need assessment in larger populations and longer durations.
Practical Application
This pilot study is not yet clinically applicable—no fully closed-loop insulin-pramlintide system is commercially available. For patients finding carbohydrate counting burdensome, simplified approaches like fixed insulin amounts for small/medium/large meals can help reduce cognitive burden.
Pramlintide (Symlin) is FDA-approved as adjunctive therapy for type 1 diabetes. For motivated patients, start with low doses and reduce mealtime insulin by 50% to minimize hypoglycemia risk.
Broader Evidence Context
Alternative approaches to fully closed-loop include ultra-rapid insulin analogs, glucose-responsive insulins, and insulin-glucagon dual-hormone systems. The FDA has signaled openness to fully closed-loop systems, with several companies pursuing regulatory approval for more automated approaches.
Study Limitations
Small pilot study (12 participants) with short duration. Long-term pramlintide tolerability not assessed. Specialized equipment not commercially available. Generalizability to broader T1D population uncertain.
Bottom Line
A fully closed-loop insulin-pramlintide system maintains glycemic control comparable to hybrid closed-loop without requiring carbohydrate counting, bringing the field closer to a true artificial pancreas. Larger confirmatory trials are needed before clinical implementation.
Source: Odabassian M, et al. “A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System.” Read article.